AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28075381 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 86
Study 28075381 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs
Number of subjects: 86
Study 26604725 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose hip powder (Hyben Vital)
Number of subjects: 34
Study 26604725 — intervention group
Group type: COMPARATOR
Intervention: Astaxanthin
Number of subjects: 34
Study 23623474 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (COC)
Number of subjects: 40
Study 23623474 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system
Number of subjects: 40
Study 23623474 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel-releasing implant
Number of subjects: 40
Study 23623474 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper intrauterine device (IUD)
Number of subjects: 40
Study 23623474 — intervention group
Group type: COMPARATOR
Intervention: No contraceptive use (control group)
Number of subjects: 40
Study 20430565 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling programs with advice about nicotine replacement therapy (and additional bupropion‐SR in one of the programs)
Number of subjects: 667
Study 20430565 — intervention group
Group type: COMPARATOR
Intervention: Usual care (periodic regular check‐ups and COPD information)
Number of subjects: 667
Study 19644802 — intervention group
Group type: EXPERIMENTAL
Intervention: Etofibrate 1000 mg/day for up to 12 months
Number of subjects: 296
Study 19644802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 17955657 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 17955657 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 0
Study 17955657 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 0
Study 15450547 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency contraception (EC) knowledge and experience
Number of subjects: 10918
Study 15450547 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency contraception (EC) use
Number of subjects: 10918
Study 15450547 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct knowledge of EC
Number of subjects: 10918
Study 15450547 — intervention group
Group type: EXPERIMENTAL
Intervention: History of EC use
Number of subjects: 10918
Study 12003484 — intervention group
Group type: EXPERIMENTAL
Intervention: Powerclean toothbrush
Number of subjects: 78
Study 12003484 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 78
Study 17294628 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-glass sealant
Number of subjects: 25
Study 17294628 — intervention group
Group type: EXPERIMENTAL
Intervention: Delton Plus
Number of subjects: 25
Study 17294628 — intervention group
Group type: COMPARATOR
Intervention: Delton (conventional sealant)
Number of subjects: 25
Study 8092223 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 30
Study 8092223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 30
Study 8092223 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 3383611 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release naproxen (750 mg)
Number of subjects: 12
Study 3383611 — intervention group
Group type: COMPARATOR
Intervention: Standard naproxen (750 mg)
Number of subjects: 12
Study 29804360 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 474
Study 29804360 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 474
Study 29804360 — intervention group
Group type: COMPARATOR
Intervention: Dietary control alone
Number of subjects: 474
Study 28243834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Tanshinone IIA Sulfonate (STS) 60 mg/day
Number of subjects: 42
Study 28243834 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 42
Study 25756440 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (fracture fixation or humeral head replacement)
Number of subjects: 250
Study 25756440 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment (sling immobilization)
Number of subjects: 250
Study 25756440 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 250
Study 25756440 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 250
Study 23351488 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 4 ml/kg
Number of subjects: 10
Study 21597111 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration oxygen (8 l/min via medium concentration mask)
Number of subjects: 106
Study 21597111 — intervention group
Group type: COMPARATOR
Intervention: Titrated oxygen (to achieve oxygen saturations between 93% and 95%)
Number of subjects: 106
Study 18455330 — intervention group
Group type: EXPERIMENTAL
Intervention: High PKA staining intensity (image analysis, continuous variable)
Number of subjects: 80
Study 18455330 — intervention group
Group type: EXPERIMENTAL
Intervention: High PKA staining intensity (image analysis, dichotomized variable)
Number of subjects: 80
Study 18455330 — intervention group
Group type: EXPERIMENTAL
Intervention: High PKA staining intensity (manual analysis)
Number of subjects: 80
Study 18455330 — intervention group
Group type: EXPERIMENTAL
Intervention: High PKA staining intensity (image analysis, continuous)
Number of subjects: 80
Study 18455330 — intervention group
Group type: EXPERIMENTAL
Intervention: High PKA staining intensity (image analysis, dichotomized)
Number of subjects: 80
Study 16580376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation with rhLH (150 IU daily) and rhFSH
Number of subjects: 120
Study 16580376 — intervention group
Group type: COMPARATOR
Intervention: rhFSH alone
Number of subjects: 120
Study 16580376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation with rhLH and rhFSH
Number of subjects: 120
Study 12513950 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day)
Number of subjects: 0
Study 12513950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10690979 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg suppositories for 21 days
Number of subjects: 50
Study 10690979 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories for 21 days
Number of subjects: 50
Study 9176035 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 0
Study 9176035 — intervention group
Group type: COMPARATOR
Intervention: L-lysine infusion
Number of subjects: 0
Study 9176035 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study 8010430 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Anesthesia (EA)
Number of subjects: 20
Study 8010430 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 20
Study 2809781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (0.25 mg/kg)
Number of subjects: 60
Study 2809781 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 60
Study 2809781 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (dexamethasone and placebo)
Number of subjects: 60
Study 863813 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered air plus 0.75 ppm ozone (PO test)
Number of subjects: 13
Study 31733006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine-lidocaine complex
Number of subjects: 586
Study 31733006 — intervention group
Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 586
Study 31594919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (4 mg daily for 21 days every 4 weeks) and dexamethasone (40 mg weekly)
Number of subjects: 136
Study 31594919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (4 mg daily for 21 days every 4 weeks) and dexamethasone (40 mg weekly) + cyclophosphamide (300 mg/m2 if less than minimal response after three cycles)
Number of subjects: 136
Study 31594919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide and dexamethasone combination
Number of subjects: 136
Study 31594919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide and dexamethasone combination with cyclophosphamide
Number of subjects: 136
Study 28440526 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-stitch transverse colostomy (observation group, n=35)
Number of subjects: 70
Study 28440526 — intervention group
Group type: COMPARATOR
Intervention: Traditional transverse colostomy (control group, n=35)
Number of subjects: 70
Study 26962712 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter inserted at the sciatic nerve bifurcation
Number of subjects: 128
Study 26962712 — intervention group
Group type: COMPARATOR
Intervention: Catheter inserted 5 cm proximal to the bifurcation
Number of subjects: 128
Study 23506308 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (20 U)
Number of subjects: 271
Study 23506308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 21803324 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular glycerol‐cryopreserved corneal tissue (GCCT)
Number of subjects: 64
Study 21803324 — intervention group
Group type: COMPARATOR
Intervention: Fresh corneal tissue (FCT)
Number of subjects: 64
Study 19397474 — intervention group
Group type: EXPERIMENTAL
Intervention: low sodium + 100mg losartan + 25 mg hydrochlorothiazide
Number of subjects: 32
Study 19397474 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 17142656 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.5 mg·kg-1 po administered 20-30 min preoperatively
Number of subjects: 30
Study 17142656 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study 17142656 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 30
Study 15304970 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy external gamma‐irradiation
Number of subjects: 18
Study 11737034 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of pets (dogs)
Number of subjects: 454
Study 11737034 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of pets (cats)
Number of subjects: 454
Study 11737034 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of vermin (cockroaches)
Number of subjects: 454
Study 11737034 — intervention group
Group type: COMPARATOR
Intervention: Homes without pets or vermin
Number of subjects: 454
Study 11737034 — intervention group
Group type: EXPERIMENTAL
Intervention: Homes with pets or vermin
Number of subjects: 454
Study 8617997 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha,25(OH)2D3 (15 microgram/g Vaseline)
Number of subjects: 18
Study 8617997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1958442 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release nicotinic acid formulation (500 mg)
Number of subjects: 7
Study 1958442 — intervention group
Group type: COMPARATOR
Intervention: Rapid-release nicotinic acid formulation (500 mg)
Number of subjects: 7
Study 7082061 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) device with intravenous morphine sulfate
Number of subjects: 24
Study 7082061 — intervention group
Group type: COMPARATOR
Intervention: Standard intramuscular dosages of morphine sulfate
Number of subjects: 24
Study 7082061 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction with analgesia
Number of subjects: 24
Study 7082061 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine usage in PCA group
Number of subjects: 24
Study 31310239 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 223
Study 31310239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 223
Study 28652142 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% KNO3 dentifrice (Test 1)
Number of subjects: 249
Study 28652142 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% SnF2 dentifrice (Test 2)
Number of subjects: 249
Study 28652142 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrices (6 negative controls)
Number of subjects: 249
Study 26106009 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201
Study 26106009 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study 23689309 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous sacroplasty (PSP)
Number of subjects: 58
Study 22002109 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling and treadmill walking exercises with a home program
Number of subjects: 52
Study 22002109 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 52
Study 19563061 — intervention group
Group type: EXPERIMENTAL
Intervention: Yasmin (30 microg ethinylestradiol plus 3 mg drospirenone)
Number of subjects: 768
Study 19563061 — intervention group
Group type: COMPARATOR
Intervention: Desogestrel (30 microg ethinylestradiol plus 150 microg desogestrel)
Number of subjects: 768
Study 17563211 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent incentives for BCO reductions
Number of subjects: 37
Study 17563211 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent incentives
Number of subjects: 37
Study 15373886 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance by infectious disease specialists (IDS) in ward 1
Number of subjects: 402
Study 15373886 — intervention group
Group type: COMPARATOR
Intervention: Physicians from other specialties in ward 2
Number of subjects: 402
Study 11605110 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine hydrochloride at the trocar site
Number of subjects: 100
Study 11605110 — intervention group
Group type: COMPARATOR
Intervention: Control group (no local anesthesia)
Number of subjects: 100
Study 11605110 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (local anesthesia)
Number of subjects: 100
Study 11907935 — intervention group
Group type: COMPARATOR
Intervention: Conpremin (0.625 mg tablets)
Number of subjects: 16
Study 11907935 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic conjugated estrogens (0.625 mg tablets)
Number of subjects: 16
Study 7862712 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg cocaine IV on day 1, 25 mg cocaine IV on day 2
Number of subjects: 0
Study 7862712 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion on day 1, saline infusion on day 2
Number of subjects: 0
Study 2117066 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (5000 I.U.) and alcohol
Number of subjects: 10
Study 2117066 — intervention group
Group type: COMPARATOR
Intervention: hCG (5000 I.U.) and placebo
Number of subjects: 10
Study 353652 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Number of subjects: 93
Study 353652 — intervention group
Group type: COMPARATOR
Intervention: Placebo machine
Number of subjects: 93
Study 31832992 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal infiltration (BI) using 4% articaine
Number of subjects: 26
Study 31832992 — intervention group
Group type: COMPARATOR
Intervention: Inferior dental block (IDB) using 2% lidocaine
Number of subjects: 26
Study 31161344 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 3
Study 27386811 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based aerobic exercises (WB)
Number of subjects: 133
Study 27386811 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based aerobic exercises (LB)
Number of subjects: 133
Study 27386811 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 133
Study 25901093 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid decline in eGFR (Q1)
Number of subjects: 6083
Study 25901093 — intervention group
Group type: COMPARATOR
Intervention: Stable eGFR (Q3)
Number of subjects: 6083
Study 25901093 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid increase in eGFR (Q4)
Number of subjects: 6083
Study 23481531 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 10101
Study 23481531 — intervention group
Group type: COMPARATOR
Intervention: Diabetes mellitus
Number of subjects: 10101
Study 20957631 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing using clinician-collected samples
Number of subjects: 2670
Study 20957631 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cytology
Number of subjects: 2670
Study 20957631 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing using self-collected samples
Number of subjects: 2670
Study 19161543 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient Sprinkles
Number of subjects: 96
Study 18033629 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 10 mg alendronate and calcium
Number of subjects: 46
Study 18033629 — intervention group
Group type: EXPERIMENTAL
Intervention: Every other day 10 mg alendronate and calcium
Number of subjects: 46
Study 18033629 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 200 IU calcitonin and calcium
Number of subjects: 46
Study 18033629 — intervention group
Group type: COMPARATOR
Intervention: Control group (femoral neck)
Number of subjects: 46
Study 18033629 — intervention group
Group type: COMPARATOR
Intervention: Comparison of groups
Number of subjects: 46
Study 15222889 — intervention group
Group type: EXPERIMENTAL
Intervention: Prize draw incentive (entry to win a personal digital assistant)
Number of subjects: 1410
Study 15222889 — intervention group
Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 1410
Study 11322350 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release oxybutynin, 10 mg/d
Number of subjects: 332
Study 11322350 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine, 2 mg twice daily
Number of subjects: 332
Study 9408932 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy treatment
Number of subjects: 60
Study 9408932 — intervention group
Group type: COMPARATOR
Intervention: Land treatment
Number of subjects: 60
Study 9408932 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 9408932 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison
Number of subjects: 60
Study 8233330 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-millimeter incision
Number of subjects: 116
Study 8233330 — intervention group
Group type: COMPARATOR
Intervention: 6-millimeter incision
Number of subjects: 116
Study 8233330 — intervention group
Group type: COMPARATOR
Intervention: 11-millimeter incision
Number of subjects: 116
Study 8233330 — intervention group
Group type: COMPARATOR
Intervention: Nuclear expression group
Number of subjects: 116
Study 2878746 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (4.1 micrograms/min for 120 min)
Number of subjects: 14
Study 2878746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (0.4 micrograms/min for 120 min)
Number of subjects: 14
Study 2878746 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 14
Study 2878746 — intervention group
Group type: COMPARATOR
Intervention: Insulin (0.1 IU/kg body weight)
Number of subjects: 14
Study 31240998 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized WCST administration
Number of subjects: 85
Study 31240998 — intervention group
Group type: COMPARATOR
Intervention: Manual WCST administration
Number of subjects: 85
Study 31240998 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual and Computerized WCST administration
Number of subjects: 85
Study 30142838 — intervention group
Group type: EXPERIMENTAL
Intervention: sucrose+MLE
Number of subjects: 15
Study 30142838 — intervention group
Group type: EXPERIMENTAL
Intervention: maltose+MLE
Number of subjects: 15
Study 30142838 — intervention group
Group type: EXPERIMENTAL
Intervention: maltodextrin+MLE
Number of subjects: 15
Study 30142838 — intervention group
Group type: EXPERIMENTAL
Intervention: glucose+MLE
Number of subjects: 15
Study 30142838 — intervention group
Group type: COMPARATOR
Intervention: glucose
Number of subjects: 15
Study 27633823 — intervention group
Group type: EXPERIMENTAL
Intervention: ePROM questionnaire completed monthly
Number of subjects: 211
Study 27633823 — intervention group
Group type: COMPARATOR
Intervention: Standard paper PROM format
Number of subjects: 211
Study 25077452 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 67
Study 25077452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture (SA)
Number of subjects: 67
Study 25077452 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 67
Study 22739049 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic‐resonance mechanical vibration
Number of subjects: 29
Study 22739049 — intervention group
Group type: COMPARATOR
Intervention: No vibration (control)
Number of subjects: 29
Study 18930226 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropins in the follicular phase (group I)
Number of subjects: 40
Study 18930226 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonists and recombinant FSH in the luteal phase (group II)
Number of subjects: 40
Study 17573794 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) 3350, 17 g daily for 28 days
Number of subjects: 237
Study 17573794 — intervention group
Group type: COMPARATOR
Intervention: Tegaserod, 6 mg b.i.d. for 28 days
Number of subjects: 237
Study 15546268 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 16
Study 15546268 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (control)
Number of subjects: 16
Study 11343813 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac sodium i.m.
Number of subjects: 120
Study 11343813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9705188 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 0
Study 8047518 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based group offered free flu shots
Number of subjects: 1989
Study 8047518 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-based group offered free flu shots
Number of subjects: 1989